RxDoctor Payments Data

Peter Jacobson, MD

Internal Medicine · Brandon, FLNPI 1417915190

Payments from drug & device makers

$1,288in general payments, 2019–2025

Across 44 payments — averaging $29.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$441
  • AstraZeneca$389
  • Boehringer Ingelheim$111
  • Ascensia Diabetes Care US Inc.$76
  • E.r. Squibb & Sons, L.L.C.$72
  • Amgen$66
  • plus $133 from 5 others

What the payments were for

  • Food & beverage$1,19293%
  • Education$967%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,288 in reported general payments places this provider in the 70th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$20,156
Medicare patients
86
Services billed
236

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban59$59,683
JardianceEmpagliflozin55$57,524
FarxigaDapagliflozin Propanediol35$47,305
TrulicityDulaglutide25$43,099
OzempicSemaglutide27$30,711
JanuviaSitagliptin Phosphate17$14,506
XareltoRivaroxaban12$10,165
Lantus SolostarInsulin Glargine,hum.Rec.Anlog33$8,019
SymbicortBudesonide/Formoterol Fumarate14$4,726
Potassium Chloride42$4,385
Atorvastatin Calcium347$2,657
Gabapentin83$2,551
Levothyroxine Sodium245$2,524
Omeprazole126$2,071
Metoprolol Succinate105$1,883

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$16$59,68359 claims
Boehringer IngelheimJardiance$111$57,52455 claims
AstraZenecaFarxiga, Symbicort$389$52,03149 claims
Lilly USA, LLCTrulicity$49$43,09925 claims
MerckJanuvia$17$14,50617 claims
Johnson & JohnsonXarelto$441$10,16512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Brandon

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →